TCGA-55-8087-01A-11R-2241-07
— · cohortA1
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortA1
- subtype
- cohortA1
- age_years
- 59
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- NOTCH_SIGNALING+0.310
- HEME_METABOLISM+0.200
- TGF_BETA_SIGNALING+0.180
- CHOLESTEROL_HOMEOSTASIS+0.130
- UV_RESPONSE_DN+0.130
- ADIPOGENESIS+0.070
- PROTEIN_SECRETION+0.070
- FATTY_ACID_METABOLISM+0.010
- ANDROGEN_RESPONSE+0.000
- BILE_ACID_METABOLISM-0.030
Top 10 suppressed
- E2F_TARGETS-0.610
- G2M_CHECKPOINT-0.560
- INTERFERON_GAMMA_RESPONSE-0.520
- MYC_TARGETS_V2-0.520
- TNFA_SIGNALING_VIA_NFKB-0.500
- INTERFERON_ALPHA_RESPONSE-0.490
- MTORC1_SIGNALING-0.470
- ALLOGRAFT_REJECTION-0.460
- ANGIOGENESIS-0.440
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.440
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | C3L-00893 | — | cohortA1 | 0.910 |
| 2 | C3N-02973 | — | cohortA1 | 0.902 |
| 3 | SRR6013544 | — | cohortA1 | 0.896 |
| 4 | TCGA-78-7167-01A-11R-2066-07 | — | cohortA2 | 0.892 |
| 5 | TCGA-55-8097-01A-11R-2241-07 | — | cohortA1 | 0.890 |
| 6 | TCGA-69-7764-01A-11R-2170-07 | — | cohortA2 | 0.870 |
| 7 | SRR1516060 | — | — | 0.870 |
| 8 | SRR12475149 | — | — | 0.869 |
| 9 | TCGA-MP-A5C7-01A-11R-A262-07 | — | cohortA2 | 0.863 |
| 10 | SRR1516046 | — | — | 0.863 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 8 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| NOTCH_SIGNALING | 0.310 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.200 | Temsirolimus | — uncovered |
| TGF_BETA_SIGNALING | 0.180 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.130 | Remibrutinib | — uncovered |
| UV_RESPONSE_DN | 0.130 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.070 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.070 | Remibrutinib | — uncovered |
| FATTY_ACID_METABOLISM | 0.010 | Inavolisib | — uncovered |